Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.43T +11.1% |
| Revenue (ttm) | 857.06B +6.7% |
| Net Income | 42.33B -15.9% |
| EPS | 150.15 -15.7% |
| Shares Out | 281.89M |
| PE Ratio | 33.81 |
| Forward PE | 23.88 |
| Dividend | 160.00 (3.15%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 1,669,900 |
| Open | 5,100.00 |
| Previous Close | 5,055.00 |
| Day's Range | 5,057.00 - 5,192.00 |
| 52-Week Range | 3,660.00 - 5,243.00 |
| Beta | -0.09 |
| Analysts | Hold |
| Price Target | 4,603.57 (-9.31%) |
| Earnings Date | Nov 10, 2026 |
About Eisai
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aβ) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and o... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2026, Eisai's revenue was 825.38 billion, an increase of 4.56% compared to the previous year's 789.40 billion. Earnings were 38.56 billion, a decrease of -16.96%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for 4523 stock is "Hold." The 12-month stock price target is ¥4,604, which is a decrease of -9.31% from the latest price.
News
Merk; Eisai Win FDA Approval For WELIREG-LENVIMA In Advanced Kidney Cancer
(RTTNews) - Merck (MRK) and Eisai have received U.S. FDA approval for WELIREG (belzutifan) in combination with LENVIMA (lenvatinib) for certain adults with previously treated advanced renal cell carci...
Eisai Earnings Call Transcript: Q1 2027
Q1 2027 saw double-digit revenue and profit growth, led by LENVIMA, DAYVIGO, and Leqembi. The company is on track to meet full-year forecasts, with strong product performance, new approvals, and expanding reimbursement driving future growth.
Eisai Quarterly report: Q1 2027
Eisai has published its Q1 2027 quarterly earnings report on August 3, 2026.
Eisai Slides: Q1 2027
Eisai has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 3, 2026.
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
UK, Japan agree tech partnership and vow fighter jet progress
The leaders of Britain and Japan announced a tech partnership on Sunday designed to boost national security and create jobs, and pledged to speed up the progress of their next generation fighter jet...
Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias
Expansion of Magnolia Meals at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners NUTLEY, N.J., June 1, 2026 /PRNewswire/ -- Eisai Inc. toda...
BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi. ...
Eisai Transcript: Investor Day 2026
The company outlined a three-year plan targeting JPY 1 trillion revenue and JPY 90 billion core operating profit by FY2028, driven by growth in LEQEMBI, LENVIMA, and DAYVIGO, and a robust neurology and oncology pipeline. New financial policies, cost reforms, and annual plan updates support sustainable growth.
Eisai Slides: FY 2026
Eisai has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 25, 2026.
Eisai Earnings Call Transcript: Q4 2026
Revenue hit a record JPY 825.4B (+4.6% YoY), led by 3L products, but operating profit fell 18.8% due to fewer one-time gains and higher restructuring costs. FY 2026 targets record revenue and improved profitability, with LEQEMBI and BBM driving growth.
Eisai Quarterly report: Q4 2026
Eisai has published its Q4 2026 quarterly earnings report on May 15, 2026.
Eisai Slides: Q4 2026
Eisai has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
STOCKHOLM, May 15, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4...
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
NUTLEY, N.J., April 9, 2026 /PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) pr...
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and ot...
Eisai Earnings Call Transcript: Q3 2026
Q3 FY2025 saw 3.1% revenue growth to JPY 619.9 billion, led by strong organic performance from LENVIMA, DAYVIGO, and LEQEMBI. Operating profit declined year-on-year due to fewer one-time gains, but organic profit contribution doubled. Two oncology in-licensing deals and LEQEMBI's global expansion support future growth.
Eisai Quarterly report: Q3 2026
Eisai has published its Q3 2026 quarterly earnings report on February 9, 2026.
Eisai Slides: Q3 2026
Eisai has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 9, 2026.
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "He...
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech
Japan's Eisai will licence Shanghai Henlius Biotech's lung cancer drug Hansizhuang, paying $75 million upfront and up to $313.34 million more if milestones are met, the Chinese drugmaker said on Thurs...
Eisai Transcript: Status Update
The meeting highlighted a long-term strategy focused on sustainable value creation, social impact in dementia and global health, and robust R&D innovation. Employee engagement and communication are being strengthened, while digital and non-pharmaceutical solutions expand the ecosystem. Leadership and vision clarity remain areas for improvement.
Eisai Slides: Status Update
Eisai has posted slides in relation to its latest quarterly earnings report, which was published on December 9, 2025.